Review on Recent advancements in multi-target drug design, with an emphasis on the opportunities and challenges associated with pharmaceutical analytical techniques

POTHURAJU RAMUDU[1*], GUDURU RAJESWARI[2], PRABHAVATHI PELLAKURI[3], KODI PRUDHVI[4], JADA RANJITH[5,] P.V. KARTHEEK REDDY[6], VISWANATH V. KANDANURU[7]

[1,6]*Assistant Professor, Sastra college of pharmaceutical sciences for womans, Nellore dist-524311*
[2]*Professor & Principal, Sastra college of pharmaceutical sciences for womans. Nellore dist-524311*
[3]*Professor & Principal, Sastra college of pharmaceutical education and research centre, Nellore.*
[4]*Assistant Professor, Srivenkateswara college of pharmacy, kodavalluru, Nellore dist-524311*
[5]*Assistant Professo, Sastra college of pharmaceutical education and research, Nellore dist-524311*
[7]*Srinivasa Institute of Pharmaceutical Sciences, PeddasettyPalli, Proddatur-516361.*

***Abstract*- Multi-target drug design has emerged as a promising strategy within the pharmaceutical industry, aiming to develop therapeutic agents capable of interacting with multiple biological targets. This approach has the potential to enhance therapeutic efficacy and mitigate adverse effects compared to single-target therapies. Recent advancements in this domain have been driven by innovations in pharmaceutical analytical techniques, including cutting-edge developments in biosensors, nanomaterials, and drug delivery systems. These techniques provide precise and efficient tools for characterizing drug interactions and dynamics, offering valuable insights into the effects and mechanisms of multi-target drugs. Nonetheless, challenges persist, such as the complexity of predicting drug behavior in biological systems, the need for improved biocompatibility and stability of drug formulations, and the development of more accurate and rapid analytical methodologies. This article reviews the recent advancements in multi-target drug design and examines the opportunities and challenges associated with pharmaceutical analytical techniques, underscoring their pivotal role in advancing drug development.**

***Keywords:* Multi-target drug design, pharmaceutical analytical techniques, drug delivery systems, biosensors, nanomaterials, therapeutic efficacy, biocompatibility.**

I. INTRODUCTION

1.1 Multi-target drug design and its importance in modern drug discovery

Multi-target drug design, also referred to as polypharmacology, entails the development of compounds that interact with multiple biological targets. This approach has garnered substantial attention in recent years, largely due to the intricate nature of multifactorial diseases such as cancer, inflammation, and metabolic syndromes. In contrast to the traditional "one target-one drug" paradigm, multi-target drug design aims to exploit the interactions among various biological pathways, potentially resulting in additive or synergistic therapeutic effects.

The significance of multi-target drug design in contemporary drug discovery is considerable. It offers a strategy to address the resilience of complex diseases characterized by multiple interacting pathways and feedback mechanisms that frequently lead to drug resistance and therapeutic inefficacy. By engaging multiple targets, multi-target drugs can circumvent or mitigate issues of drug resistance, which poses a substantial challenge in treating chronic and multifactorial diseases.

Moreover, multi-target drug design facilitates the exploration of orphan targets, which remain underexplored due to a lack of known physiological roles or modulators. This aspect expands the potential for discovering therapeutic targets and drugs that may have been overlooked in single-target approaches. Consequently, it represents a promising avenue for developing novel treatments

for complex diseases that lack effective therapeutic options [1].

With advancements in modern drug discovery technologies, such as in vitro pharmacological methods, computational technologies, crystallography, and fragment-based design, the development of multi-target drugs is becoming more systematic and less reliant on serendipity. These tools enable a more rational and targeted approach in identifying suitable target combinations, thereby facilitating the design of compounds with optimal therapeutic profiles [2].

1.2 Examine the shift from single-target to multi-target approaches

The transition from single-target to multi-target strategies in drug discovery signifies a substantial advancement in pharmaceutical research. Historically, drug discovery has concentrated on single-target methodologies, wherein drugs were engineered to interact with specific biological targets, typically proteins, to achieve therapeutic effects. This focus was primarily due to the relative simplicity of identifying a single, well-defined target and designing drugs accordingly. However, the intricate nature of biological systems and diseases often involves multiple pathways and targets, rendering single-target strategies less effective for complex diseases such as cancer and neurodegenerative disorders. The multi-target approach, also referred to as polypharmacology, recognizes that modulating multiple targets concurrently can result in improved therapeutic outcomes. This shift is driven by the recognition that diseases are seldom the consequence of a single dysfunctional pathway. Consequently, drugs capable of binding to multiple targets are more effective in managing diseases with complex pathophysiology. Progress in computational and AI-assisted technologies has been instrumental in this transition, enabling researchers to predict how drugs interact with multiple targets simultaneously. These technologies facilitate the *in-silico* exploration of extensive chemical and biological spaces, aiding in the identification and optimization of multi-target drug candidates. Furthermore, the integration of computational methods with experimental approaches assists in designing drugs that can specifically modulate multiple proteins involved in disease pathways, thereby enhancing therapeutic efficacy and minimizing side effects. While the traditional single-target approach remains valuable for certain conditions, the multi-target approach is increasingly vital in addressing diseases with a multifactorial basis. This paradigm shift is supported by emerging technologies and an improved understanding of disease mechanisms, rendering multi-target drug discovery an essential strategy in contemporary pharmacology.

1.3 Need for advanced analytical techniques in this field

The deployment of advanced analytical techniques across various disciplines has become increasingly crucial due to the complexity and sophistication of contemporary challenges. In the financial sector, algorithmic trading and machine learning necessitate sophisticated methods such as time series analysis, natural language processing, and deep learning to enhance market predictions and develop efficient trading strategies [3]. Environmental protection heavily relies on instrumental methods such as spectrometry and chromatography for monitoring pollutants, facilitating compliance monitoring, and supporting sustainable practices [4].

In the domain of food safety and environmental monitoring, nano-liquid chromatography has emerged as a pivotal tool, enhancing sensitivity and resolution for analyzing pharmaceuticals, pesticides, and mycotoxins [5]. Similarly, the authenticity of food products such as honey is safeguarded using techniques like isotope ratio mass spectrometry, with isotope techniques aiding in identifying adulteration [6].

In biomedical research, the analysis of single-cell RNA-sequencing data increasingly relies on deep learning methods, which can address computational challenges in quality control, normalization, and detailed downstream analysis [7]. Analytical advancements also contribute significantly to the study of red blood cells, where sophisticated Raman spectroscopy offers non-destructive and detailed molecular insights necessary for diagnosing RBC-related diseases [8].

II. RECENT PROGRESS

2.1Advancements in computational methods for multi-target drug design

Recent advancements in computational methodologies for multi-target drug design have achieved significant progress by employing a range of sophisticated tools and techniques that enhance the drug discovery process. A primary approach in this domain is network pharmacology, which integrates systems biology, pharmacology, and computational techniques to address complex disease mechanisms by mapping biological networks [9]. This approach facilitates the prediction of drug behavior, drug repurposing, and the identification of novel therapeutic targets, rendering it particularly beneficial for diseases such as cancer and neurodegenerative disorders.

Machine learning (ML) and artificial intelligence (AI) have also been instrumental in advancing multi-target drug design. These technologies streamline the process, enabling the exploration of target-ligand interactions, de novo drug design, and the prediction of adverse effects [10]. Specifically, AI contributes to drug design, polypharmacology, and the prediction of drug properties, although challenges such as data quality and generalizability persist [11].

Quantum mechanics-based techniques have enhanced the prediction of molecular structures and interactions, thereby facilitating more accurate drug design and optimization [12]. When combined with techniques from bioinformatics and data mining, these methods allow for efficient exploration of chemical and biological spaces, thereby enhancing target identification and personalized medicine.

Polypharmacology, which involves the design of drugs targeting multiple biological pathways, offers a promising strategy for treating complex diseases. Computational methods such as multi-target virtual screening and algorithms like collaborative filtering have been developed to predict protein targets for new chemicals, thereby overcoming the challenge of sparse interaction data.

Furthermore, the development of user-friendly computational platforms, such as LigAdvisor, integrates diverse data sources, making it accessible for various drug design tasks, including drug repurposing and polypharmacology [13].

2.2 Explore the use of artificial intelligence and machine learning inpredicting drug-target interactions

The integration of artificial intelligence (AI) and machine learning (ML) in predicting drug-target interactions is transforming pharmaceutical research and development. AI and ML techniques are employed to analyze extensive datasets, facilitating the rapid identification of drug targets and the prediction of compound efficacy. These technologies enhance various aspects of drug discovery, including target identification, by utilizing advanced modeling techniques and prediction algorithms.

AI's ability to process vast libraries of chemical compounds expeditiously aids in the screening and selection of potential drug candidates. This rapid processing results in fewer false positives and negatives and enhances the accuracy of predicting drug-target interactions through ensemble techniques and predictive modeling [14]. In particular, AI models can predict interactions between drugs and target proteins, increasing the likelihood of identifying viable therapeutic targets [15].

The application of AI in this domain is not without challenges, such as data quality, model interpretability, and ethical considerations. However, addressing these challenges holds promise for AI to significantly transform the healthcare landscape by delivering safer and more effective medicines [16].

2.3. High-throughput screening techniques for multi-target compounds

High-throughput screening (HTS) has markedly advanced the identification of multi-target compounds, thereby enhancing the drug discovery process. A significant development is the expansion of HTS methodologies from simple systems, which involve single targets or binding affinity, to more complex systems, such as cell-based assays. This evolution is driven by the urgent need for novel antimicrobial compounds capable of overcoming drug-resistant microorganisms. High-throughput technologies are increasingly focused on these multi-target assays, which are crucial for discovering effective antimicrobial agents [17].

Moreover, HTS has incorporated mass spectrometry (MS) techniques, which reduce method development time by eliminating the need for labeled reagents. MS-based HTS offers high selectivity and sensitivity, efficiently processing

large-scale compound libraries. Techniques such as multiplexed electrospray liquid chromatography tandem mass spectrometry have been adapted to effectively screen complex targets, thereby broadening the scope of HTS to targets that are traditionally challenging to screen using other methods [18].

Recent HTS implementations also underscore the importance of assay design and target engagement. An example is the use of microscale thermophoresis (MST) to confirm compound interactions with targets, ensuring that resources are directed toward validating genuine hits. Such biophysical methods are now integral to the later stages of HTS triage, enhancing the validation processes during screening campaigns [19].

In the context of collaborative and open-access environments, HTS is fostering innovation by integrating academic and industrial efforts. This collaboration maximizes research capabilities and expands the discovery pipeline, particularly for rare and neglected diseases. The alignment of best practices from the pharmaceutical industry with academic research initiatives is anticipated to enhance the quality and reach of drug discovery efforts [20].

2.4. Examine developments in structure-based drug design for multi-target drugs

Recent advancements in structure-based drug design (SBDD) have significantly progressed in exploiting the potential of multi-target drugs through various innovative methodologies and computational advancements. A primary focus of recent research has been enhancing the prediction of binding free energies, which is crucial for multi-target drug design. This has been facilitated by advancements in molecular dynamics (MD) simulations, enabling detailed modeling of conformational changes critical to the binding process. Improved predictive accuracy and computational capabilities have rendered MD-based virtual screening a viable tool in drug development, particularly for multi-target drugs, by employing approaches such as Molecular Mechanics Poisson Boltzmann Surface Area (MM-PBSA) and Linear Interaction Energy (LIE) [21].

Nanotechnological advancements have also significantly contributed to drug design strategies. For instance, nanodiamonds have been explored for their capacity to carry multiple drugs simultaneously, offering potential for combination therapies, which is a vital aspect of multi-target drug design. These nanodiamonds enhance drug loading efficiency, stability, and controlled release through surface functionalization and encapsulation techniques. They also enable site-specific drug delivery, which is advantageous for multi-target therapies, allowing different drug components to act synergistically at their respective target sites [22].

Furthermore, dendrimers, which are highly branched, star-shaped macromolecules, have emerged as promising vehicles for drug delivery due to their ability to host multiple active drug molecules. Recent research has focused on the development of stimuli-responsive dendrimer systems, which can dissociate drugs in response to specific internal signals, making them ideal for designing multi-target drugs that need to be released under different physiological conditions or target sites. These advancements in dendrimer technologies underscore their application in developing novel combination treatments that leverage multi-target drug strategies [23].

Moreover, nanoparticle-based systems have demonstrated promise in overcoming challenges associated with multi-target drug delivery, such as crossing the blood-brain barrier for central nervous system therapeutics. By fine-tuning properties such as size, shape, and surface charge, researchers have enhanced the delivery efficiency of these nanoparticles, facilitating the precise targeting of multiple therapeutic agents across different physiological barriers [24].

These innovations collectively underscore a transformative phase in structure-based drug design, where multi-target capabilities are being expanded through integrated computational and nanotechnological strategies, paving the way for more effective and precisely targeted therapeutic solutions. While these advancements offer promising prospects, continued research is necessary to enhance biocompatibility and address any remaining delivery challenges in multi-target drug design.

III. OPPORTUNITIES

3.1 Potential for improved efficacy and reduced side effects with multi-target drugs

Multi-target drugs, designed to interact with multiple biological targets, have shown considerable potential in enhancing efficacy and reducing side effects compared to traditional single-target drugs. These drugs are particularly effective for complex, multifactorial diseases such as cancer, inflammation, and metabolic syndromes.

Improved Efficacy: The rationale behind multi-target drugs lies in their ability to produce additive or synergistic effects by modulating multiple pathways simultaneously. This approach holds promise for overcoming drug resistance, a common issue with single-target therapies, by targeting various points within the disease network. The interaction of these drugs with multiple macromolecular targets can lead to improved therapeutic outcomes. For instance, in cancer treatment, multi-target therapies can inhibit various aspects of tumor growth and survival, thereby enhancing treatment efficacy.

Reduced Side Effects:Multi-target drugs have the potential to minimize adverse effects due to their ability to balance on-target efficacy and off-target interactions. By precisely targeting multiple related pathways or components in a disease process, these drugs can lower the required dose of each individual drug component, thereby reducing the potential for toxicity. For example, network pharmacology approaches enable the design of drugs that systematically attack disease networks at different levels, reducing susceptibility to side effects typically caused by high doses in single-target therapies.

Modern drug discovery increasingly relies on computational models and network pharmacology strategies to design effective multi-target therapies. These techniques leverage advances in cheminformatics, bioinformatics, and systems biology to predict drug-target interactions and optimize the drug profile for efficacy and safety prior to experimental validation.
While multi-target drug development faces challenges, such as the complexity of simultaneous target modulation, ongoing advances in structural systems pharmacology and computational methods hold great promise for realizing their full potential in creating more effective and safer therapeutic options [25].

3.2 Explore the possibility of repurposing existing drugs for new therapeutic applications

Drug repurposing, also known as drug repositioning, is an innovative strategy focusing on discovering new therapeutic uses for existing drugs. This approach leverages the known safety profiles and pharmacodynamics of approved drugs to reduce the time and cost associated with traditional drug development.

There are several methodologies employed in drug repurposing, including experimental and computational approaches. Traditional methods, while effective, can be time-consuming and expensive. Now, artificial intelligence (AI) has been integrated into drug repurposing to efficiently analyze large-scale datasets, predicting potential new uses for existing drugs. AI, coupled with virtual screenings, has shown significant promise in identifying hidden patterns within drug response data.

The advantages of drug repurposing extend beyond cost and time savings. It also maximizes the therapeutic value of drugs by targeting rare, neglected, and difficult-to-treat diseases. This necessitates fewer clinical trials, as the safety of the drug has already been established, thereby reducing the risk of failure.

Recent strategies have combined bioinformatics with high-throughput data, enhancing our understanding of molecular mechanisms and drug-target interactions, which contribute significantly to drug repurposing initiatives [26]. These approaches have recently been utilized to address public health emergencies, such as the COVID-19 pandemic, by quickly identifying potential therapeutic candidates from existing drugs [27].

Despite the potential benefits, drug repurposing faces regulatory and administrative challenges. Standardizing regulatory processes and addressing the high costs associated with repurposing trials remain significant hurdles. However, the ongoing advancements in computational methodologies and AI integration continue to offer promising solutions to these challenges.

Overall, drug repurposing presents a promising and cost-effective approach for expanding therapeutic applications while accelerating the drug development process. This is particularly crucial for treating rare and neglected diseases, potentially revolutionizing the field of pharmacology and therapeutics [28].

3.3 Highlight the potential for addressing complex diseases with multi-target approaches

Multi-target approaches in the treatment of complex diseases hold considerable promise due to their capacity to address the multifactorial nature of these conditions. Diseases such as Alzheimer's, diabetes, and various cancers often involve multiple interrelated pathological processes. Consequently, targeting multiple molecular pathways simultaneously can enhance therapeutic efficacy compared to traditional single-target drugs.

A notable area where multi-target strategies demonstrate potential is in the treatment of neurodegenerative diseases. Alzheimer's disease (AD), for instance, is characterized by several pathological features, including amyloid-β (Aβ) aggregation, tau protein hyperphosphorylation, oxidative stress, and neuroinflammation. Conventional single-target treatments often fall short because they do not adequately address the complex interplay of these factors. However, multi-target-directed ligands (MTDLs) have been increasingly explored as they offer a comprehensive approach to modulating various interacting targets.

Another example is the use of Traditional Chinese Medicine (TCM) in Alzheimer's therapy. TCM compounds exhibit multi-target characteristics that potentially render them more advantageous over single-target drugs by modulating numerous aspects of the disease simultaneously, such as neuroinflammation and oxidative stress [29].

Furthermore, multi-target strategies are employed in the development of treatments targeting a broader range of complex disorders. For instance, hydrogen sulfide (H2S) donating compounds have been formulated to target various pathways in inflammatory-based diseases and cancers, improving treatment outcomes by leveraging the multifactorial nature of these conditions [30].

Despite their potential, designing multi-target drugs involves significant challenges, including selecting appropriate target combinations, balancing drug affinities, and ensuring drug-likeness and safety. In silico methods, such as inverse docking and machine learning, are valuable tools in optimizing these compounds [31].

Overall, multi-target drug approaches offer a promising avenue for developing more effective treatments for complex diseases by addressing the intricate pathophysiological networks involved. However, these strategies require careful design and optimization to ensure efficacy and safety in clinical application.

3.4 Opportunity for personalized medicine through multi-target drug design

The potential for personalized medicine through multi-target drug design is substantial, as it addresses the complexity and multifactorial nature of numerous diseases that traditional single-target drugs may not effectively treat. Multi-target drugs, or polypharmacology, involve designing compounds that can act on multiple biological targets, which is particularly advantageous for conditions such as cancer, inflammation, and metabolic disorders [2].

Personalized medicine seeks to tailor treatments to individuals based on their unique genetic makeup and disease characteristics. This approach is enhanced by integrating technologies such as artificial intelligence, multi-omics analysis, and computational drug design. These technologies facilitate a deeper understanding of disease mechanisms and the development of drugs that can target multiple pathways simultaneously, potentially increasing therapeutic efficacy and reducing side effects [32].

Reinforcement learning and AI-driven technologies have revolutionized drug design by optimizing treatment plans and predicting drug-target interactions through multi-omics data integration. These advances facilitate the creation of personalized treatment plans by considering patients' unique genetic and molecular profiles, including pharmacogenomics, which improves drug selection and dosage adjustments.

Furthermore, the development of protein drugs based on proteoformics—the study of distinct

protein forms—has underscored the importance of personalized approaches in drug therapy. This focus on proteoforms allows for the design of drugs that can specifically target variations in protein expressions that may affect individual responses to treatments [33].

Polypharmacology also presents opportunities for drug repurposing and innovation in drug delivery systems, such as using peptide and protein nanostructures for targeted delivery and controlled release in precision medicine [34]. Tools like LigAdvisor facilitate these processes by integrating various data sources, enabling more efficient drug discovery and development tailored to meet personalized therapeutic needs [13].

IV. RESULTS

The progression of symptoms in patients who were diagnosed with PD was confirmed by physical examination – with observed results of involuntary, stiff, slow - movements and loss of balance and leaning postures. And by imaging examination with the help of MRI which is only limited to ruling out structural abnormalities, confirming age-related cerebral atrophy in 12 patients in our study. Gradual improvements of motor manifestations were observed by pharmacological treatment. The patients diagnosed with clinical features and given treatment regimens can see in (Table: 02), with a stay period of 97 patients 06-10 days and 23 patients 11-15 days. About 77 patients are Men diagnosed with PD than women (Table: 01). Patients were highly diagnosed with tremors along with/without other conditions. A patient who was diagnosed with PD was prescribed Levodopa + Carbidopa LD/CD (100/10mg) with variable doses and frequencies based on their conditions. About 11 patients received 110mg × 02 frequencies, 30 patients received 110mg × 03, 67 patients received 110mg × 04, and 12 patients received 110mg × 05 doses. Along with levodopa + carbidopa, several patients were prescribed adjuvants like pramipexole 0.25mg once a day (OD) 1 hour before bedtime, selegiline 5mg OD, and Entacapone 200mg OD after 3 days of initial therapy of LD/CD. Patients who experienced – weakness and were diagnosed with age-related cerebral atrophy were administered Vitamin B12 and Multivitamin tablets OD at noon time. And the Betahistine 8mg OD or BD, or 16 mg OD prescribed for vertigo and anxiety disorders. Deriphyllin® taken for Shortness of Breath. In contrast, azithromycin has been used for throat infections. The NSAIDs and Gastritis regimens were prescribed usually according to the patient's conditions. Abnormal motor symptoms with following therapeutic regimens by day-by-day follow-up show significant improvements in patients diagnosed with PD. About 25% after 5 days of follow-up showed slight and 67% after 10 days of follow-up showed moderate -PD symptom reduction along with other clinical features associated with it. In contrast 25% of patients show symptomatic improvement when treated without LD/CD adjuvants.

V. CHALLENGES IN PHARMACEUTICAL ANALYTICAL TECHNIQUES:

4.1. Examine the complexity of analyzing drug-target interactions for multiple targets

The potential for personalized medicine through multi-target drug design is substantial, as it addresses the complexity and multifactorial nature of numerous diseases that traditional single-target drugs may not effectively treat. Multi-target drugs, or polypharmacology, involve designing compounds that can act on multiple biological targets, which is particularly advantageous for conditions such as cancer, inflammation, and metabolic disorders [2].

Personalized medicine aims to tailor treatments to individuals based on their unique genetic makeup and disease characteristics. This approach is enhanced by integrating technologies such as artificial intelligence, multi-omics analysis, and computational drug design. These technologies facilitate a deeper understanding of disease mechanisms and the development of drugs that can target multiple pathways simultaneously, potentially increasing therapeutic efficacy and reducing side effects [32].

Furthermore, the development of protein drugs based on proteoformics—the study of distinct protein forms—has underscored the importance of personalized approaches in drug therapy. This focus on proteoforms allows for the design of drugs that can specifically target variations in protein expressions that may affect individual responses to treatments [33].

Polypharmacology also presents opportunities for drug repurposing and innovation in drug delivery

systems, such as using peptide and protein nanostructures for targeted delivery and controlled release in precision medicine [34]. Tools like LigAdvisor facilitate these processes by integrating various data sources, enabling more efficient drug discovery and development tailored to meet personalized therapeutic needs [13].

4.2. Challenges in developing appropriate in vitro and in vivo models for multi-target drugs

The development of suitable in vitro and in vivo models for multi-target drugs presents numerous challenges. Primarily, the complexity of accurately replicating human physiological conditions in these models is considerable. Advanced in vitro systems, such as organ-on-a-chip models, strive to emulate human physiology more closely than traditional cell culture platforms or animal models. Although promising, these systems continue to encounter issues related to reproducibility, reliability, and their practical implementation in pharmaceutical contexts.

There is a persistent demand for models that can accurately represent drug interactions within human tissues, given that traditional animal models frequently fail to predict human responses accurately. This discrepancy often results in late-stage failures in clinical trials, which are both costly and time-consuming. In multistage screenings that incorporate computational models alongside traditional methods, reliability and predictive accuracy remain inadequate, leading to high attrition rates of drug candidates [35].

Furthermore, the translation of multi-target drugs from discovery to clinical application is inherently complex due to the necessity for a comprehensive understanding of the interactions between the drug and various biological targets. This requires the development of models capable of reliably simulating multi-target interactions. However, current drug discovery processes are not fully equipped to effectively address the multitarget nature of certain diseases [36].

The integration of advanced platforms such as organ-on-chip offers potential solutions but also introduces challenges related to standardization, scalability, and the transition from experimental models to widespread application in the drug development pipeline. Despite these challenges, ongoing advancements in these areas hold the promise of enhancing the predictive accuracy of preclinical testing, thereby potentially reducing the time and cost of drug development and increasing the likelihood of successful clinical outcomes.

4.3. Explore the difficulties in optimizing pharmacokinetic and pharmaco-dynamic properties for multiple targets

One significant difficulty is the intrinsic complexity of predicting drug responses, which are influenced by interactions at multiple targets. These interactions complicate the understanding of how information flows through cellular networks, affecting the biological system's complete response to the drug [37]. Indeed, understanding the interplay of pharmacodynamics (PD) and pharmacokinetics (PK) across different targets is challenging due to varying binding affinities and the distinct pharmacokinetic profiles required by each target to achieve the desired level of therapeutic effect [38].

Additionally, the structural diversity and properties of multi-target compounds present unique formulation challenges, such as ensuring bioavailability and optimizing drug delivery to each target within different tissues. The design and optimization of hybrid drugs further add to the complexity, requiring the integration of multiple pharmacophores with differing physicochemical properties [39].

To address these challenges, sophisticated computational methodologies, systems biology approaches, and network pharmacology have been employed. These integrate biological and pharmacological data to identify optimal target combinations and predict drug behavior across multiple cellular pathways [9]. Despite advancements, these methods face constraints, such as incomplete biological data and the computational complexity of simulating biological systems [9].

4.4 Highlight the challenges in predicting and managing potential drug-drug interactions

The prediction and management of potential drug-drug interactions (DDIs) are essential for ensuring patient safety and effective pharmacotherapy. However, these tasks present several challenges:

1. Complexity of Drug Interactions: DDIs frequently involve intricate biochemical mechanisms that are challenging to predict with accuracy. Pharmacokinetic interactions, wherein one drug influences the metabolism of another, necessitate precise knowledge of the drugs' metabolic pathways and the enzymes involved, such as the cytochrome P450 enzymes.
2. Incomplete Data: Existing public and proprietary sources of DDI information are often incomplete and may be inaccurate, complicating reliance on these sources for predictions. The limitations of pre-market clinical studies often result in not all DDIs being identified before a drug is widely used [40].
3. Genetic Variability: Genetic differences among individuals, such as variations in the CYP2D6 enzyme, can affect the metabolic rate of drugs, leading to variability in DDIs. This genetic variability adds an additional layer of complexity in predicting potential interactions, as it influences drug metabolism differently among patients [41].
4. Pharmacovigilance and Real-World Evidence: The detection of DDIs in post marketing scenarios relies on pharmacovigilance systems, which utilize diverse sources such as the US FDA Adverse Event Reporting System and electronic health records. The heterogeneous nature of these sources presents challenges in data integration and consistency, as well as in identifying truly novel interactions among large volumes of data.
5. Technological and Methodological Challenges: Predictive models employing link prediction, similarity-based models, and neural networks must manage complex, high-dimensional data. These models require detailed, multidimensional input features, including molecular structures and drug target information, to predict DDIs accurately. Implementing these models at scale and ensuring their accuracy and reliability remains a significant challenge.
6. Consumer Health Information: Patients frequently combine over-the-counter drugs, prescriptions, and supplements, which are not always captured in clinical databases, resulting in potential gaps in understanding the full scope of DDIs [42].

V. EMERGING ANALYTICAL TECHNIQUES:

5.1 Advancements in mass spectrometry for multi-target drug analysis

Recent advancements in mass spectrometry (MS) have markedly improved its utility in multi-target drug analysis, facilitated by innovations in methodologies, instrumentation, and data analysis. A significant development in this field is the emergence of Data-Independent Acquisition Mass Spectrometry (DIA-MS), which has advanced to offer comprehensive and reproducible proteome profiling. DIA-MS is particularly advantageous for creating permanent digital maps of biological systems. enabling retrospective analyses crucial for multi-target drug discovery [43].

A further notable advancement is the utilization of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. HDX-MS is a robust method for investigating protein dynamics, interactions, and folding, which are critical for comprehending drug interactions with multiple targets. This technique has been extensively employed to characterize biotherapeutics and elucidate protein-small molecule interactions, rendering it invaluable for multi-target drug development [44].

Moreover, spatially resolved metabolomics, facilitated by mass spectrometry imaging (MSI), provides novel insights into the spatial distribution of metabolites within tissues. This approach enables the visualization and mapping of metabolites with high precision, thereby enhancing our understanding of disease mechanisms, drug toxicity, and therapeutic efficacy. The integration of MSI with artificial intelligence is anticipated to advance precision medicine and expedite multi-target drug development [45].

Additionally, high-resolution mass spectrometry (HRMS) has emerged as a pivotal tool in pharmaceutical development, offering detailed analyte characterization, screening, and quantification across various applications. HRMS is particularly valuable for identifying small molecules

and novel drug modalities, which are crucial for multi-target drug strategies [46].

5.2 Explore the use of nuclear magnetic resonance spectroscopy in studying drug-target interactions

Nuclear Magnetic Resonance (NMR) spectroscopy is an essential technique for investigating drug-target interactions, particularly in the realm of drug discovery and development. It is a powerful tool capable of evaluating the structures and dynamics of biomolecules under physiological conditions [47]. NMR has numerous practical applications in drug discovery, including hit identification, lead optimization, and fragment-based drug design (FBDD).

A notable advantage of NMR is its capacity to examine molecular interactions at an atomic level. It provides critical insights into protein-ligand interactions, such as the identification of binding sites, binding modes, and ligand affinities [48]. Importantly, NMR can detect these interactions even when they are too weak to be identified by other methods such as ELISA or fluorescence resonance energy transfer (FRET) [49].

One of the prominent NMR techniques is 19F-NMR spectroscopy, which is highly sensitive due to the absence of fluorine in biological systems and provides valuable information on fragment screening. It has proven effective for identifying weakly binding fragments that can be optimized into potent drug candidates [50].

NMR's utility extends to understanding complex biochemical interactions in living cells, offering physiologically relevant insights into biomolecular mechanisms [51]. The technique's ability to perform in-cell studies further enhances its application in elucidating how drugs interact with targets within their native cellular environments.

Additionally, NMR is employed in conjunction with other biophysical techniques in a synergistic manner to enhance the drug discovery process [52]. High-Throughput Screening by NMR (HTS by NMR), for instance, combines fragment-based screening with combinatorial chemistry to address challenges such as targeting protein-protein interactions, which are typically difficult to drug [53].

5.3 Highlight the potential of surface plasmon resonance in multi-target binding studies

Surface plasmon resonance (SPR) technology offers substantial potential for multi-target binding studies due to its capacity for real-time, label-free analysis of molecular interactions. A primary advantage of SPR in these applications is its high sensitivity and ability to provide quantitative data on binding kinetics, which is essential for understanding complex biological interactions [54].

SPR imaging sensors have been particularly influential in advancing multi-target studies because they facilitate the simultaneous monitoring of multiple interactions. The capability to analyze multiple analytes in parallel not only enhances throughput but also provides comprehensive binding profiles that are critical for multi-target drug discovery and diagnostic applications [55]. Additionally, the use of multiplex spectral-phase SPR imaging biosensors further enhances the potential for high-throughput biosensing applications, rendering them suitable for large-scale biological studies and medical diagnostics [54].

The versatility of SPR is also demonstrated through its integration with other technologies. For instance, combining SPR with surface acoustic wave (SAW) measurements allows for simultaneous optical and acoustic data collection, enriching the analysis of complex biomolecular interactions by providing complementary insights [56]. Such hybrid systems can enhance the robustness and informativeness of binding interaction studies.

Overall, SPR technology, particularly through its imaging capabilities and innovative sensor designs, provides a powerful platform for multi-target binding studies, offering detailed insights into molecular interactions with high sensitivity and specificity. This makes it a vital tool in the fields of drug discovery, diagnostics, and various fundamental biological research areas [57].

5.4 Examine the role of cryo-electron microscopy in visualizing complex drug-target interactions

Cryo-electron microscopy (cryo-EM) has emerged as a pivotal technique in structural biology, significantly enhancing the visualization of intricate drug-target interactions. This method offers high-

resolution structural characterization of biological macromolecules, which is essential for structure-based drug design. It facilitates detailed analysis of druggable targets that are difficult to study using other methods such as X-ray crystallography, including integral membrane proteins like G protein-coupled receptors (GPCRs) and ion channels [58].

The ability of cryo-EM to determine structures at near-atomic resolution enables it to capture macromolecular interactions in their native environment. This capability bridges the gap between structural and cell biology, which is beneficial for understanding pathogen biology and drug discovery processes [59]. The technique is particularly effective in visualizing macromolecular complexes in situ, providing insights that are crucial for developing drugs and understanding host-pathogen interactions.

Advanced applications of cryo-EM, such as time-resolved cryo-EM, offer the potential to observe dynamic protein-ligand interactions and drug-binding kinetics. This capability supports a dynamics-based approach to drug discovery, allowing scientists to identify novel druggable conformations and understand allosteric regulation, ultimately improving pharmacological modeling and reducing drug development timelines [60].

The industrial adoption of cryo-EM has expanded, as evidenced by the establishment of facilities dedicated to structure-based drug design in collaboration with pharmaceutical companies and research institutions. This industrial expansion underscores cryo-EM's reliability, reproducibility, and throughput improvements, which are necessary for early-stage drug discovery [61].

Moreover, recent advancements in cryo-EM, such as fragment-based drug discovery (FBDD), enable the detailed visualization of molecular interactions between drug fragments and proteins, demonstrating the technique's applicability and effectiveness in identifying potential therapeutic compounds [62].

VI. FUTURE DIRECTIONS

6.1 Discuss the need for standardization in multi-target drug design and analysis

Standardization in multi-target drug design and analysis is essential for optimizing the drug discovery process and ensuring the effective integration of diverse biological data. As the paradigm shifts from the "one target, one drug" model to a "multi-target, multi-drug" approach, the complexity of designing drugs that interact with multiple biological targets necessitates standardization for several reasons.

Firstly, the integration of various types of data, including genomic, proteomic, signaling, and metabolomic data, is crucial for constructing comprehensive networks that elucidate the molecular basis of diseases. These networks can reveal novel drug interactions and targets [63]. Without standardized methods and terminology, integrating data from different sources can be challenging, leading to inconsistencies and unreliable conclusions.

Moreover, the design of drugs with specific polypharmacological profiles is inherently complex. Computational tools and data-driven approaches are integral to efficiently mining chemical, biological, clinical, and disease-related data for drug discovery tasks such as drug repurposing and polypharmacology. Platforms such as LigAdvisor integrate information from various databases to facilitate drug design, underscoring the need for standardized data formats for seamless integration and exploitation of these resources [13].

In the context of network-based drug discovery and the use of medicinal herbs for polypharmacology, the need for standardization becomes even more pronounced. The integration of multiple 'omics' platforms with herbal medicine databases is crucial for developing network-based multi-target drugs, but this process is hindered by the lack of standardized methodologies and terminologies. Enhancing public databases and increasing research efforts using system biology platforms could improve the reliability and utility of these integrated approaches [64].

Lastly, understanding the interactions at the network level, especially with complex drug-target pairs such as those in the human kinome, underscores the importance of standardization. Standardized frameworks can improve the comparative analysis of multi-target drugs and combination products, aiding in the identification of optimal drug design strategies and target interactions [65].

6.2 Explore the potential for integrating various analytical techniques for comprehensive drug profiling

The integration of diverse analytical techniques for comprehensive drug profiling presents a multifaceted strategy for monitoring, characterizing, and ensuring the quality and safety of pharmaceutical products. This integration capitalizes on the strengths of various analytical methods to offer a more complete understanding of drug properties, impurities, and metabolite profiles.

1. High-Performance Liquid Chromatography (HPLC): HPLC remains a fundamental technique renowned for its speed, specificity, and accuracy in drug analysis. It plays a vital role in optimizing methods for drug detection, separation, and quantification, rendering it indispensable across drug discovery, development, and manufacturing processes [66].

2. Liquid Chromatography-Mass Spectrometry (LC-MS): The combination of liquid chromatography with mass spectrometry is a potent approach, particularly for metabolite profiling. This technique provides high sensitivity and specificity, facilitating the characterization and quantification of a broad spectrum of compounds. It is extensively employed in monitoring impurity profiles and supporting pharmaceutical development and safety evaluations

3. Raman Spectroscopy: This method is advantageous for its non-destructive analysis and minimal sample preparation. It is particularly useful in monitoring drug distribution, polymorph distribution, and illegal drug analysis. Advanced Raman imaging techniques further enhance its utility in qualitative and quantitative analyses in pharmaceutical settings [67].

4. Quality by Design (QbD): The QbD approach in analytical method development emphasizes a systematic understanding of product and process, aiding in minimizing variability and ensuring robust analytical performance throughout a drug's lifecycle. This methodology is pivotal in developing stress-testing protocols and in understanding drug stability and behavior under various conditions [68].

5. Metabolomics: Techniques such as NMR spectroscopy, GC-MS, and CE-MS are employed for global metabolite analysis, which is essential for toxicology and biomarker discovery. These methods, coupled with multivariate statistical analyses, enable the differentiation of healthy versus diseased states and are integral to biomedical research [69].

6. Phyto cannabinoid Profiling: For specific applications such as cannabis products, a variety of chromatographic and spectroscopic methods are employed for profiling Phyto cannabinoids. The development of these methods aids in quality control and in correlating Phyto cannabinoid profiles with pharmacological effects [70].

By integrating these diverse analytical techniques, pharmaceutical researchers can achieve comprehensive drug profiling. This approach not only supports the development of safer and more effective pharmaceutical products but also meets regulatory standards for quality and safety assurance. Each technique contributes unique strengths, and their combined use offers a robust framework for in-depth drug analysis.

6.3 Highlight the importance of developing predictive models for multi-target drug efficacy and toxicity

The development of predictive models for assessing the efficacy and toxicity of multi-target drugs is essential for advancing drug discovery and enhancing patient outcomes. Multi-target drug strategies are imperative due to the intricate nature of diseases such as cancer and metabolic disorders, which frequently involve multiple pathways and targets. Predictive models facilitate the identification of drug candidates capable of effectively modulating multiple targets, thereby augmenting therapeutic efficacy while minimizing adverse effects.

Polypharmacology, which entails the design of drugs that can interact with multiple targets, has gained prominence due to its potential to offer improved drug profiles, including reduced side effects and enhanced therapeutic success. By comprehending the complex interactions between drugs and multiple targets, researchers can better predict both efficacy and toxicity outcomes [71]. This approach employs computational and experimental

methods to balance efficacy and safety in drug design [72].

The integration of artificial intelligence (AI) and machine learning (ML) in this domain has transformed the predictive modeling landscape by enabling precise prediction of drug-target interactions, pharmacological evaluation, and experimental validation [73]. These technologies contribute to the creation of more effective and safer drugs by optimizing chemical properties, screening drug candidates, and predicting potential toxicity [74].

Furthermore, understanding multi-target interactions aids in mitigating systemic toxicities that often accompany potent drugs. For instance, the application of nanocarriers in drug delivery systems underscores how targeted delivery can reduce cardiotoxicity and other side effects of potent therapeutic agents such as platinum-based drugs [75].

6.4 Discuss the role of systems biology in advancing multi-target drug design

Systems biology is pivotal in advancing multi-target drug design by offering a comprehensive framework for understanding the complex networks of biological systems and their interactions with drugs. This approach transitions from the traditional "one-target, one-drug" paradigm to "target-network, multi-component therapeutics" [76]. By incorporating systems biology, researchers can integrate and analyze complex datasets, facilitating a deeper understanding of biological complexity and interactions at multiple levels [77].

The integration of systems biology into drug discovery has led to the development of network pharmacology, which enhances efficacy while reducing toxicity by modulating multiple targets instead of a single one. This is particularly significant as selective compounds often exhibit lower clinical efficacy compared to multi-target drugs due to the robustness of phenotypic networks [78]. Network pharmacology thus expands the potential for druggable targets by integrating network biology and polypharmacology, which is vital for advancing multi-target drug design

Systems-based approaches facilitate the rational design of multi-target drugs by utilizing computational tools and high-throughput data analysis to model disease networks and identify potential target sets, thereby broadening the range of possible therapeutic interventions[79]

Additionally, network-based strategies in systems biology assist in predicting interactions within cellular pathways, which can guide the structure-based design of multi-target drugs. These strategies provide insights into potential side effects and predict how drug interactions may propagate through biological networks [80].

VII. CONCLUSION

Recent progress in designing drugs that target multiple areas has greatly affected medicine. These drugs work on several targets at once, which is important for treating complex diseases. A major step forward is the creation of photo responsive drug delivery systems (PDDSs). These systems use light to control when and where drugs are released, making treatments more precise and effective. However, there are still challenges in using these drugs in real-life treatments. These include making sure drugs build up in the right places, delivering them accurately, and getting them deep into tissues

Analytical techniques are key to improving multi-target drug design. Super-resolution imaging is very important in biology. It helps scientists see and study tiny interactions. This detail is needed to find multiple targets in biological systems, which helps create specific multi-target drugs. Also, carbon nanotube-based field-effect transistor (CNT-FET) biosensors make diagnostics faster and more accurate. This is important for checking how well new drug designs work and if they are safe. Improving these techniques is crucial for solving current problems and making multi-target drug therapies successful in clinics.

The future of multi-target drug design in treatment strategies is promising. By targeting several pathways, these drugs could offer better treatment options for diseases like cancer and neurodegenerative disorders. This method not only aims to improve treatment effectiveness but also to reduce side effects of traditional single-target therapies. New drug delivery methods and advanced analytical tools are paving the way for personalized medicine, where treatments are customized for each patient for the best results.

REFERENCES

[1] Stefan SM, Rafehi M. Medicinal polypharmacology:Exploration and exploitation of the polypharmacolome in

modern drug development. *Drug Development Research*. 2023;85(1). doi:10.1002/ddr.22125

[2] Proschak E, Merk D, Stark H. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. *Journal of Medicinal Chemistry*. 2018;62(2):420-444. doi:10.1021/acs.jmedchem.8b00760

[3] Adesina M, Iloh D, Michael C, et al. Algorithmic trading and machine learning: Advanced techniques for market prediction and strategy development. *World Journal of Advanced Research and Reviews*. 2024;23(2):979-990. doi:10.30574/wjarr.2024.23.2.2405

[4] Durmishi B, Shabani A, Durmishi A. THE ROLE OF INSTRUMENTAL METHODS IN CHEMICAL ANALYSIS FOR ENVIRONMENTAL PROTECTION. *International Journal of Chemistry & Materials Sciences (IJCMS)*. Published online February 25, 2025:1. doi:10.58885/ijcms.v10i1.001.bd

[5] Fedorenko D, Bartkevics V. Recent Applications of Nano-Liquid Chromatography in Food Safety and Environmental Monitoring: A Review. *Critical Reviews in Analytical Chemistry*. 2021;ahead-of-print(ahead-of-print):98-122. doi:10.1080/10408347.2021.1938968

[6] Walker MJ, Cowen S, Gray K, Hancock P, Burns DT. Honey authenticity: the opacity of analytical reports - part 1 defining the problem. *NPJ Science of Food*. 2022;6(1). doi:10.1038/s41538-022-00126-6

[7] Bao S, Qu J, Zhou M, Li K, Zhang Z, Yan C. Deep learning-based advances and applications for single-cell RNA-sequencing data analysis. *Briefings in Bioinformatics*. 2021;23(1). doi:10.1093/bib/bbab473

[8] Dybas J, Alcicek FC, Wajda A, et al. Trends in biomedical analysis of red blood cells – Raman spectroscopy against other spectroscopic, microscopic and classical techniques. *TrAC Trends in Analytical Chemistry*. 2021;146:116481. doi:10.1016/j.trac.2021.116481

[9] Joshi CP, Baldi A, Kumar N, Pradhan J. Harnessing network pharmacology in drug discovery: an integrated approach. *Naunyn-Schmiedeberg's archives of pharmacology*. 2024;398(5):4689-4703. doi:10.1007/s00210-024-03625-3

[10] Liu X, Xue Z, Luo M, Ke B, Lv J. Anesthetic drug discovery with computer-aided drug design and machine learning. *Anesthesiology and Perioperative Science*. 2024;2(1). doi:10.1007/s44254-023-00047-x

[11] Abbas MKG, Rassam A, Abunora R, Karamshahi F, Abouseada M. The Role of AI in Drug Discovery. *Chembiochem : a European journal of chemical biology*. 2024;25(14). doi:10.1002/cbic.202300816

[12] Yuguda Y, Dhanushya J, Kolli T, Unuebho I. Emerging trends in computational approaches for drug discovery in molecular biology. *GSC Biological and Pharmaceutical Sciences*. 2023;24(3):202-213. doi:10.30574/gscbps.2023.24.3.0340

[13] Pinzi L, Tinivella A, Gagliardelli L, Rastelli G, Beneventano D. LigAdvisor: a versatile and user-friendly web-platform for drug design. *Nucleic Acids Research*. 2021;49(W1):W326-W335. doi:10.1093/nar/gkab385

[14] Husnain A, Rasool S, Hussain HK, Saeed A. Revolutionizing Pharmaceutical Research: Harnessing Machine Learning for a Paradigm Shift in Drug Discovery. *International Journal of Multidisciplinary Sciences and Arts*. 2023;2(2):149-157. doi:10.47709/ijmdsa.v2i2.2897

[15] Han R, Lee H, Yoon H, Kim G, Lee Y. Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. *Pharmaceuticals*. 2023;16(9):1259. doi:10.3390/ph16091259

[16] Kant S, Deepika D, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. *Discover Pharmaceutical Sciences*. 2025;1(1). doi:10.1007/s44395-025-00007-3

[17] E Blondelle S, Lohner K. Optimization and High-Throughput Screening of Antimicrobial Peptides. *Current Pharmaceutical Design*. 2010;16(28):3204-3211. doi:10.2174/138161210793292438

[18] Roddy TP, Kenney KL, Wang YK, et al. Mass Spectrometric Techniques for Label-free High-Throughput Screening in Drug Discovery. *Analytical Chemistry*. 2007;79(21):8207-8213. doi:10.1021/ac062421q

[19] Rainard JM, Pandarakalam GC, Mcelroy SP. Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective. *Slas Discovery*. 2018;23(3):225-241. doi:10.1177/2472555217744728

[20] Roy A, Chaguturu R, R Mcdonald P, Sittampalam S. Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making. *Current Pharmaceutical Biotechnology*. 2010;11(7):764-778. doi:10.2174/138920110792927757

[21] King E, Aitchison E, Li H, Luo R. Recent Developments in Free Energy Calculations for Drug Discovery. *Frontiers in molecular biosciences*. 2021;8. doi:10.3389/fmolb.2021.712085

[22] Singh D, Ray S. A short appraisal of nanodiamonds in drug delivery and targeting: recent advancements. *Frontiers in Nanotechnology*. 2023;5. doi:10.3389/fnano.2023.1259648

[23] Wang J, Qiao X, Li B, Qiu L, Yang H. Dendrimer-based drug delivery systems: history, challenges, and latest developments. *Journal of Biological Engineering*. 2022;16(1):18. doi:10.1186/s13036-022-00298-5

[24] Nayak U, Halagali P, Panchal KN, et al. Nanoparticles in CNS Therapeutics: Pioneering Drug Delivery Advancements. *Current pharmaceutical design*. 2025;31(6):443-460. doi:10.2174/0113816128328722240828184410

[25] Zhang W, Xiao W, Wang Y, Bai Y. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective. *Current Pharmaceutical Design*. 2016;22(21):3171-3181. doi:10.2174/1381612822666160224142812

[26] Patel B, Soni M, Rathaur P, Sr KJ, Gelat B. Bioinformatics Perspective of Drug Repurposing. *Current Bioinformatics*. 2024;19(4):295-315. doi:10.2174/0115748936264692230921071504

[27] Pan X, He L, Yu PS, et al. Deep learning for drug repurposing: Methods, databases, and applications. *WIREs Computational Molecular Science*. 2022;12(4). doi:10.1002/wcms.1597

[28] Patrignani P, Contursi A, Tacconelli S, Steinhilber D. The future of pharmacology and therapeutics of the arachidonic acid cascade in the next decade: Innovative advancements in drug repurposing. *Frontiers in pharmacology*. 2024;15. doi:10.3389/fphar.2024.1472396

[29] Li L, Yang CC, Zhang L. Multi-Target Strategy and Experimental Studies of Traditional Chinese Medicine for Alzheimer's Disease Therapy. *Current Topics in Medicinal Chemistry*. 2015;16(5):537-548. doi:10.2174/1568026615666150813144003

[30] Corvino A, Scognamiglio A, Fiorino F, et al. Pills of Multi-Target H2S Donating Molecules for Complex Diseases. *International journal of molecular sciences*. 2024;25(13):7014. doi:10.3390/ijms25137014

[31] Zięba A, Stępnicki P, Matosiuk D, Kaczor AA. What are the challenges with multi-targeted drug design for complex diseases? *Expert Opinion on Drug Discovery*. 2022;17(7):673-683. doi:10.1080/17460441.2022.2072827

[32] Zhou Y, Wang Q, Peng S, Cai X, Wang H. Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. *Genes*. 2024;15(4):468. doi:10.3390/genes15040468

[33] Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. *Molecular & Cellular Proteomics*. 2024;23(3):100737. doi:10.1016/j.mcpro.2024.100737

[34] Kim H, Kim S, Guler MO, Taslakjian B, Tirrell MV. Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine. *ChemBioChem*. 2024;25(8). doi:10.1002/cbic.202300831

[35] Jodat YA, Shin SR, Kim GJ, et al. Human-Derived Organ-on-a-Chip for Personalized Drug Development. *Current Pharmaceutical Design*. 2019;24(45):5471-5486. doi:10.2174/1381612825666190308150055

[36] Wong EHF, Smith MA, Lee CM, Yocca F. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. *The International Journal of Neuropsychopharmacology*. 2010;13(09):1269-1284. doi:10.1017/s1461145710000866

[37] Xie L, Bourne PE, Kinnings SL, Xie L. Novel Computational Approaches to

Polypharmacology as a Means to Define Responses to Individual Drugs. *Annual Review of Pharmacology and Toxicology*. 2011;52(1):361-379. doi:10.1146/annurev-pharmtox-010611-134630

[38] Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: promises and new drugs in 2022. *Pharmacological Reports*. 2023;75(4):755-770. doi:10.1007/s43440-023-00501-4

[39] Sharma S, Babu MA, Kumar R, et al. A review on pyrimidine-based pharmacophore as a template for the development of hybrid drugs with anticancer potential. *Molecular diversity*. Published online February 12, 2025. doi:10.1007/s11030-025-11112-x

[40] Fokoue A, Zhang P, Sadoghi M, Hassanzadeh O. Predicting Drug-Drug Interactions Through Large-Scale Similarity-Based Link Prediction. In: springer; 2016:774-789. doi:10.1007/978-3-319-34129-3_47

[41] Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. *Pharmacogenomics*. 2014;15(5):655-665. doi:10.2217/pgs.14.6

[42] Vilar S, Friedman C, Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. *Briefings in Bioinformatics*. 2017;19(5):863-877. doi:10.1093/bib/bbx010

[43] Kitata RB, Chen Y, Yang J. Advances in data-independent acquisition mass spectrometry towards comprehensive digital proteome landscape. *Mass Spectrometry Reviews*. 2022;42(6):2324-2348. doi:10.1002/mas.21781

[44] Masson GR, Jenkins ML, Burke JE. An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. *Expert Opinion on Drug Discovery*. 2017;12(10):981-994. doi:10.1080/17460441.2017.1363734

[45] Min X, Zhao Y, Yu M, et al. Spatially resolved metabolomics: From metabolite mapping to function visualising. *Clinical and translational medicine*. 2024;14(11). doi:10.1002/ctm2.70031

[46] Géhin C, Holman SW. Advances in high-resolution mass spectrometry applied to pharmaceuticals in 2020: A whole new age of information. *Analytical science advances*. 2021;2(3-4):142-156. doi:10.1002/ansa.202000149

[47] Li Q, Kang C. A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery. *Molecules*. 2020;25(13):2974. doi:10.3390/molecules25132974

[48] Li Y, Kang C. Solution NMR Spectroscopy in Target-Based Drug Discovery. *Molecules*. 2017;22(9):1399. doi:10.3390/molecules22091399

[49] Sugiki T, Kojima C, Fujiwara T, Furuita K. Current NMR Techniques for Structure-Based Drug Discovery. *Molecules*. 2018;23(1):148. doi:10.3390/molecules23010148

[50] Li Q, Kang C. Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery. *Molecules (Basel, Switzerland)*. 2024;29(23):5748. doi:10.3390/molecules29235748

[51] Li C, Wu Q, Zhang X, et al. Magnetic Resonance Spectroscopy as a Tool for Assessing Macromolecular Structure and Function in Living Cells. *Annual Review of Analytical Chemistry*. 2017;10(1):157-182. doi:10.1146/annurev-anchem-061516-045237

[52] Dias DM, Ciulli A. NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes. *Progress in Biophysics and Molecular Biology*. 2014;116(2-3):101-112. doi:10.1016/j.pbiomolbio.2014.08.012

[53] Wu B, Wei J, De S, Purves A, Pellecchia M, Barile E. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. *Current Topics in Medicinal Chemistry*. 2015;15(20):2032-2042. doi:10.2174/1568026615666150519102459

[54] Wong CL, Olivo M. Surface Plasmon Resonance Imaging Sensors: A Review. *Plasmonics*. 2014;9(4):809-824. doi:10.1007/s11468-013-9662-3

[55] Kodoyianni V. Label-free analysis of biomolecular interactions using SPR imaging. *BioTechniques*. 2011;50(1):32-40. doi:10.2144/000113569

[56] Samarentsis AG, Pantazis AK, Friedt JM, Gizeli E, Tsortos A. Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and

Surface Acoustic Wave Measurements. *Sensors*. 2020;20(21):6177. doi:10.3390/s20216177

[57] Wang D, Chen J, Ho HP, et al. Recent Advances in Surface Plasmon Resonance Imaging Sensors. *Sensors*. 2019;19(6):1266. doi:10.3390/s19061266

[58] Lees JA, Dias JM, Han S. Applications of Cryo-EM in small molecule and biologics drug design. *Biochemical Society Transactions*. 2021;49(6):2627-2638. doi:10.1042/bst20210444

[59] Shepherd DC, Ghosal D, Dalvi S. From cells to atoms: Cryo-EM as an essential tool to investigate pathogen biology, host-pathogen interaction, and drug discovery. *Molecular Microbiology*. 2021;117(3):610-617. doi:10.1111/mmi.14820

[60] Mao Y. Dynamics-based drug discovery by time-resolved cryo-EM. *Current opinion in structural biology*. 2025;91:103001. doi:10.1016/j.sbi.2025.103001

[61] Sader K, Matadeen R, Castro Hartmann P, Schlichten C, Halsan T. Industrial cryo-EM facility setup and management. *Acta Crystallographica Section D Structural Biology*. 2020;76(Pt 4):313-325. doi:10.1107/s2059798320002223

[62] Saur M, Hartshorn MJ, Dong J, et al. Fragment-based drug discovery using cryo-EM. *Drug Discovery Today*. 2019;25(3):485-490. doi:10.1016/j.drudis.2019.12.006

[63] Masoudi-Nejad A, Mousavian Z, Bozorgmehr JH. Drug-target and disease networks: polypharmacology in the post-genomic era. *In Silico Pharmacology*. 2013;1(Suppl 2). doi:10.1186/2193-9616-1-17

[64] Leung EL, Jiang ZH, Liu L, Zhou H, Cao ZW. Network-based drug discovery by integrating systems biology and computational technologies. *Briefings in Bioinformatics*. 2012;14(4):491-505. doi:10.1093/bib/bbs043

[65] Li YH, Yu CY, Zhu F, et al. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective. *PLOS ONE*. 2016;11(11):e0165737. doi:10.1371/journal.pone.0165737

[66] Shinde S, Rajurkar V. Advances in High-Performance Liquid Chromatography (HPLC) Method Development and Validation: A Comprehensive Review. *Journal of Drug Delivery and Biotherapeutics*. Published online January 1, 2024. doi:10.61920/jddb.v1i03.109

[67] Ren J, Mao S, Lin J, Xu Y, Xu N, Zhu Q. Research Progress of Raman Spectroscopy and Raman Imaging in Pharmaceutical Analysis. *Current Pharmaceutical Design*. 2022;28(18):1445-1456. doi:10.2174/1381612828666220518145635

[68] Vyas AJ, Patel AB, Shah SR, Patel AI, Patel NK, Visana NM. Analytical Quality by Design in Stress Testing or Stability - Indicating Method. *Asian Journal of Pharmaceutical Analysis*. 2021;11(2):170-178. doi:10.52711/2231-5675.2021.00029

[69] Issaq HJ, Muschik GM, Veenstra TD, Van QN, Waybright TJ. Analytical and statistical approaches to metabolomics research. *Journal of Separation Science*. 2009;32(13):2183-2199. doi:10.1002/jssc.200900152

[70] Stefkov G, Kulevanova S, Stoilkovska Gjorgievska V, et al. Analytical Techniques for Phytocannabinoid Profiling of Cannabis and Cannabis-Based Products-A Comprehensive Review. *Molecules (Basel, Switzerland)*. 2022;27(3):975. doi:10.3390/molecules27030975

[71] Liu X, Ye K, Ijzerman AP, Emmerich MTM, Van Westen GJP, Van Vlijmen HWT. DrugEx v2: de novo design of drug molecules by Pareto-based multi-objective reinforcement learning in polypharmacology. *Journal of Cheminformatics*. 2021;13(1). doi:10.1186/s13321-021-00561-9

[72] Ravikumar B, Aittokallio T. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. *Expert Opinion on Drug Discovery*. 2017;13(2):179-192. doi:10.1080/17460441.2018.1413089

[73] Afrose N, Bhowmick P, Bhowmick M, Hazra A, Chakraborty R. AI-Driven Drug Discovery and Development. In: igi global; 2024:259-277. doi:10.4018/979-8-3693-3629-8.ch013

[74] Guo W, Hong H, Khan MKH, et al. Review of machine learning and deep learning models for toxicity prediction. *Experimental Biology and Medicine*. 2023;248(21). doi:10.1177/15353702231209421

[75] Yamashita A, Zeng L, Choi HS, et al. H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs.

International Journal of Molecular Sciences. 2023;24(20):15466. doi:10.3390/ijms242015466

[76] Rai A, Ramakrishnan V, Kumar V, Jerath G, Kartha CC. Mapping drug-target interactions and synergy in multi-molecular therapeutics for pressure-overload cardiac hypertrophy. *npj Systems Biology and Applications*. 2021;7(1). doi:10.1038/s41540-021-00171-z

[77] Arrell DK, Terzic A. Network Systems Biology for Drug Discovery. *Clinical Pharmacology & Therapeutics*. 2010;88(1):120-125. doi:10.1038/clpt.2010.91

[78] Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nature Chemical Biology*. 2008;4(11):682-690. doi:10.1038/nchembio.118

[79] Prathipati P, Mizuguchi K. Systems Biology Approaches to a Rational Drug Discovery Paradigm. *Current Topics in Medicinal Chemistry*. 2015;16(9):1009-1025.doi:10.2174/1568026615666150826114524

[80] Engin H, Gursoy A, Nussinov R, Keskin O. Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View. *Current Pharmaceutical Design*. 2014;20(8):1201-1207. doi:10.2174/13816128113199990066